SCHEMBL2807973

SCHEMBL2807973

CCOC(=O)c1cc(OC(C)=O)c2ccc(F)cc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
BCL2L1 Q07817 1/20 0.43
MAPT P10636 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
CASP3 P42574 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALPL P05186 1/20 0.41
GAA P10253 1/20 0.41
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA7 P43166 3/20 0.41
CA9 Q16790 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3330717 0.87 BCL2L1 (0.45) BCL2L1MAPTNPC1RAB9AALDH1A1
SCHEMBL16479442 0.86 ALDH1A1 (0.54) TSHRBCL2L1MAPTKMT2AMEN1
SCHEMBL16474350 0.85 LMNA (0.50) TSHRBCL2L1MAPTKMT2AMEN1
SCHEMBL13005288 0.85 ALDH1A1 (0.43) BCL2L1MAPTKMT2ANPC1RAB9A
SCHEMBL3328123 0.83 HTT (0.48) TSHRBCL2L1MAPTKMT2AMEN1
SCHEMBL30299154 0.81 BCL2L1 (0.53) TSHRBCL2L1MAPTKMT2AMEN1
SCHEMBL2805615 0.81 BCL2L1 (0.53) TSHRBCL2L1MAPTKMT2AMEN1
SCHEMBL13131932 0.81 TSHR (0.42) TSHRBCL2L1MAPTKMT2AMEN1
SCHEMBL16474346 0.81 NPC1 (0.49) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL30259994 0.80 BCL2L1 (0.41) BCL2L1MAPTKMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
EP-2168952-A1 MORPHOLINE DERIVATIVE Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 TSHR 807/4885BCL2L1 3766/4885MAPT 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.